EyePoint Pharmaceuticals, Inc. (EYPT) Earnings Call Analysis
NASDAQ · Healthcare · Biotechnology
Earnings Reports
-
EYPT Q1 2026: $88M R&D Spend Accelerates DuraView Phase 3, Eyes Midyear AMD Data Catalyst
May 06, 2026
-
EYPT Q4 2025: R&D Spend Climbs 45% as DuraView Nears Phase III Data Inflection
March 04, 2026
-
EyePoint (EYPT) Q3 2025: $172M Financing Extends Runway Past Phase 3 Wet AMD Data
November 05, 2025
-
EYPT Q2 2025: Phase 3 Enrollment Surges Past 800, Securing First-to-File Lead for DuraView
August 06, 2025
-
EYPT Q1 2025: R&D Spend Up 63% as DuraView Phase 3 Enrollment Surges Past 90%
July 06, 2025